Zobrazeno 1 - 10 of 20 pro vyhledávání: '"Latifa Hassaine"'
6
Abstract 2019: Oxidative phosphorylation (OXPHOS) dependency predicts response to the Polo-like kinase 1 (PLK1) inhibitor onvansertib in a phase 1b/2 of relapsed/refractory acute myeloid leukemia (R/R AML)
Autor: Mark G. Erlander, Brittany Ross, Latifa Hassaine, Maya Ridinger, Marion Luebbermann, Peter J. P. Croucher, Errin Samuelsz
Publikováno v: Cancer Research. 80:2019-2019
Background: PLK1, a serine-threonine kinase and key regulator of the cell cycle, controls mitotic entry and progression. PLK1 is overexpressed in AML and its inhibition induces G2/M arrest, apoptosis and tumor growth inhibition in AML preclinical mod
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8070896150aaf1560bb11a08bf8c35d2
https://doi.org/10.1158/1538-7445.am2020-2019
Zobrazit plný text záznamu
7
Abstract A43: Plasma-derived circulating tumor DNA (ctDNA) as a surrogate biomarker for treatment response with the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with LDAC or decitabine in acute myeloid leukemia (AML)
Autor: Brittany Ross, Errin Samuelsz, Mark Erlander, Maya Ridinger, Marion Luebbermann, Latifa Hassaine
Publikováno v: Clinical Cancer Research. 26:A43-A43
Background: Cancer cells from solid tumors release ctDNA into the bloodstream, clinically enabling assessment, monitoring tumor mutational heterogeneity, treatment response, minimal residual disease (MRD), and disease progression. However, the clinic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f521890a15e24841491617d825775644
https://doi.org/10.1158/1557-3265.liqbiop20-a43
Zobrazit plný text záznamu
8
BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease
Autor: Karena Kosco, Filip Janku, Lorieta Leppin, Patrick P. Lin, Razelle Kurzrock, Latifa Hassaine, Jason C. Poole, Cecile Rose T. Vibat, Mark Erlander, Funda Meric-Bernstam, Vanda M. Stepanek, Veronica R. Holley, Goran Cabrilo
Publikováno v: Oncotarget
Oncotarget, vol 5, iss 11
Erdheim-Chester disease (ECD) is a rare histiocytosis with a high prevalence of BRAF V600E mutation (>50% of patients). Patients with BRAF-mutant ECD can respond to BRAF inhibitors. Unfortunately, the lack of adequate archival tissue often precludes
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8651ec88ad797a3f4d3c08dd55d3b22a
https://doi.org/10.18632/oncotarget.1964
Zobrazit plný text záznamu
9
Abstract 4833: Pharmacodynamic and tumor biomarker analysis of a PLK1 inhibitor, PCM-075, in a phase 1b/2 trial for acute myeloid leukemia
Autor: Mark G. Erlander, Latifa Hassaine, Jeffrey N. Miner, Maya Ridinger, Karena Kosco
Publikováno v: Cancer Research. 78:4833-4833
Acute myeloid leukemia (AML) is an aggressive hematologic disease that is characterized by the accumulation of immature myeloid precursor cells. Treatment options for patients are selected based on factors such as age, comorbidities, and cytogenetics
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6c0a53cbef747548d00296e5ffa5f251
https://doi.org/10.1158/1538-7445.am2018-4833
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje